FR3044017B1 - Procede de transfection transitoire pour la production retrovirale - Google Patents

Procede de transfection transitoire pour la production retrovirale Download PDF

Info

Publication number
FR3044017B1
FR3044017B1 FR1661254A FR1661254A FR3044017B1 FR 3044017 B1 FR3044017 B1 FR 3044017B1 FR 1661254 A FR1661254 A FR 1661254A FR 1661254 A FR1661254 A FR 1661254A FR 3044017 B1 FR3044017 B1 FR 3044017B1
Authority
FR
France
Prior art keywords
transient transfection
transfection method
bacs
retroviral production
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1661254A
Other languages
English (en)
French (fr)
Other versions
FR3044017A1 (fr
Inventor
Sabine Johnson
Celeste PALLANT
Eirini Vamva
Conrad Vink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1520764.0A external-priority patent/GB201520764D0/en
Priority claimed from GBGB1609354.4A external-priority patent/GB201609354D0/en
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of FR3044017A1 publication Critical patent/FR3044017A1/fr
Application granted granted Critical
Publication of FR3044017B1 publication Critical patent/FR3044017B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FR1661254A 2015-11-24 2016-11-21 Procede de transfection transitoire pour la production retrovirale Expired - Fee Related FR3044017B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB15207640 2015-11-24
GBGB1520764.0A GB201520764D0 (en) 2015-11-24 2015-11-24 Transient transfection method for retroviral production
GB16093544 2016-05-26
GBGB1609354.4A GB201609354D0 (en) 2016-05-26 2016-05-26 Transient transfection method for retroviral production

Publications (2)

Publication Number Publication Date
FR3044017A1 FR3044017A1 (fr) 2017-05-26
FR3044017B1 true FR3044017B1 (fr) 2019-05-03

Family

ID=57348703

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1661254A Expired - Fee Related FR3044017B1 (fr) 2015-11-24 2016-11-21 Procede de transfection transitoire pour la production retrovirale

Country Status (15)

Country Link
US (2) US10450574B2 (enExample)
EP (1) EP3380605A1 (enExample)
JP (1) JP7110096B2 (enExample)
KR (1) KR102067352B1 (enExample)
CN (1) CN108291211A (enExample)
AU (1) AU2016359838B2 (enExample)
BR (1) BR112018010639A2 (enExample)
CA (1) CA3006285A1 (enExample)
DE (1) DE102016122317A1 (enExample)
FR (1) FR3044017B1 (enExample)
IL (1) IL259223B (enExample)
IT (1) IT201600117287A1 (enExample)
RU (1) RU2749717C2 (enExample)
SA (1) SA518391585B1 (enExample)
WO (1) WO2017089307A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016185125A1 (fr) * 2015-05-15 2016-11-24 Vectalys Particule rétrovirale comportant au moins deux arn non viraux encapsidés
FR3044016A1 (fr) * 2015-11-24 2017-05-26 Glaxosmithkline Ip Dev Ltd Lignees cellulaires stables pour la production retrovirale
GB201706121D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
GB201715052D0 (en) 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
FI3633040T3 (fi) * 2017-12-22 2023-08-03 Oxford Biomedica Ltd Retrovirusvektori
GB201816919D0 (en) * 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
CN110684804B (zh) * 2019-10-15 2023-04-18 上海本导基因技术有限公司 递送外源rnp的慢病毒载体及其制备方法
GB202004371D0 (en) 2020-03-26 2020-05-13 Glaxosmithkline Ip Dev Ltd CAR constructs
GB202005096D0 (en) 2020-04-07 2020-05-20 Glaxosmithkline Modified vectors for production of retrovirus
CN117377691A (zh) 2021-03-19 2024-01-09 葛兰素史密斯克莱知识产权发展有限公司 靶向密蛋白3的嵌合抗原受体和治疗癌症的方法
CN113373266B (zh) * 2021-06-22 2022-07-01 内蒙古农业大学 一种用于检测绵羊肺腺瘤病毒的荧光rpa引物、试剂盒和检测方法
EP4422787A1 (en) 2021-10-28 2024-09-04 Southwest Research Institute Devices for cell separation
EP4698215A1 (en) 2023-04-19 2026-02-25 GlaxoSmithKline Intellectual Property Development Limited Cytotoxicity targeting chimeras for car-t and car-nk cells
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
WO2026032970A1 (en) 2024-08-07 2026-02-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Cd4-specific chimeric antigen receptor and methods and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
ATE309000T1 (de) * 1995-06-27 2005-11-15 Bavarian Nordic As Verkapselte zellen die virenpartikeln produzieren
WO1997030169A1 (en) 1996-02-13 1997-08-21 Fred Hutchinson Cancer Research Center 10a1 retroviral packaging cells and uses thereof
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
US6277621B1 (en) 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
ATE384795T1 (de) 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
WO2000065077A1 (en) 1999-04-22 2000-11-02 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
US6677155B1 (en) 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
EP1173597A1 (en) 1999-04-29 2002-01-23 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
EP1100884A1 (en) 1999-06-07 2001-05-23 Cell Genesys, Inc. Hybrid yeast-bacteria cloning system and uses thereof
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
WO2001091802A1 (en) 2000-05-30 2001-12-06 Baylor College Of Medicine Chimeric viral vectors for gene therapy
WO2002022663A2 (en) 2000-09-18 2002-03-21 Maxygen, Inc. Stress resistant retroviruses
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002053576A1 (en) 2001-01-05 2002-07-11 The General Hospital Corporation Viral delivery system for infectious transfer of large genomic dna inserts
DE10111433A1 (de) 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
JP4489424B2 (ja) 2001-05-30 2010-06-23 グラクソ グループ リミテッド 染色体に基くプラットホーム
US6835568B2 (en) 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
DK2348119T3 (en) 2002-02-01 2017-08-21 Oxford Biomedica (Uk) Ltd Polycistronic lentiviral vector
DE60333001D1 (de) 2002-04-10 2010-07-29 Us Gov Health & Human Serv Vac-bac-shuttlevektor-system
ATE365220T1 (de) * 2002-11-25 2007-07-15 Bavarian Nordic As Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
CN1965086B (zh) * 2004-04-28 2012-12-26 宾夕法尼亚大学托管会 多价病毒载体和产生它的系统
US20080226677A1 (en) 2004-05-06 2008-09-18 Yasuko Mori Recombinant virus vector for gene transfer into lymphoid cells
EP1652932A1 (en) 2004-11-02 2006-05-03 GBF Gesellschaft für Biotechnologische Forschung mbH Method for the generation of virus producing cell lines and cell lines
JP2008521405A (ja) 2004-11-24 2008-06-26 ナノヴェクター・リミテッド ウイルスベクター
EP1829963A4 (en) * 2004-11-24 2009-01-28 Anaeropharma Science Inc NEW SHUTTLE VECTOR
EP2062246A4 (en) 2006-08-18 2010-09-29 Univ North Carolina VACCINES AGAINST CHIMARICAL VIRUSES
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
US20110027313A1 (en) 2008-04-04 2011-02-03 University Of Miami Viral recombineering and uses thereof
WO2012028681A1 (en) 2010-09-02 2012-03-08 Molmed Spa Stable production of lentiviral vectors
US9273324B2 (en) 2010-12-05 2016-03-01 Andrew S. Belmont Recombinant gene expression
WO2012170431A2 (en) 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
WO2014043131A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of California Lentiviral vector for stem cell gene therapy of sickle cell disease
EP3117004A4 (en) * 2014-03-14 2017-12-06 University of Washington Genomic insulator elements and uses thereof
GB2538324A (en) 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Packaging cell line for retroviral production
GB2538321A (en) 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Artificial chromosome for retroviral production
KR102058113B1 (ko) * 2015-11-23 2019-12-23 주식회사 엘지화학 접착력이 개선된 리튬 이차전지용 전극 및 이의 제조방법
FR3044016A1 (fr) 2015-11-24 2017-05-26 Glaxosmithkline Ip Dev Ltd Lignees cellulaires stables pour la production retrovirale

Also Published As

Publication number Publication date
FR3044017A1 (fr) 2017-05-26
AU2016359838B2 (en) 2020-08-06
IL259223A (en) 2018-07-31
WO2017089307A1 (en) 2017-06-01
RU2018118964A (ru) 2019-12-26
RU2018118964A3 (enExample) 2020-04-02
KR102067352B1 (ko) 2020-01-16
IL259223B (en) 2022-05-01
BR112018010639A2 (pt) 2019-01-22
KR20180073624A (ko) 2018-07-02
JP7110096B2 (ja) 2022-08-01
AU2016359838A1 (en) 2018-05-24
EP3380605A1 (en) 2018-10-03
JP2019500030A (ja) 2019-01-10
DE102016122317A1 (de) 2017-05-24
IT201600117287A1 (it) 2018-05-21
US20200063144A1 (en) 2020-02-27
CA3006285A1 (en) 2017-06-01
CN108291211A (zh) 2018-07-17
SA518391585B1 (ar) 2020-10-26
US20170145427A1 (en) 2017-05-25
US10450574B2 (en) 2019-10-22
RU2749717C2 (ru) 2021-06-16

Similar Documents

Publication Publication Date Title
MX2017016688A (es) Nuevas enzimas y sistemas crispr.
SA523441205B1 (ar) التحرير المتعدد للجينوم
BR112018010635A2 (pt) linhagens celulares estáveis para a produção retroviral
MX2022002872A (es) Nuevas sistemas y enzimas de crispr dirigidos a adn.
MX372651B (es) ARN SINTÉTICO PARA SU Uso EN EL TRATAMIENTO DE LA EPIDERMÓLISIS AMPOLLOSA DISTRÓFICA.
MX382822B (es) Metodos y productos para transfeccion de celulas.
EA202091673A1 (ru) Способ амплификации нуклеиновых кислот
BR112018010639A2 (pt) método de transfecção transitória para produção retroviral.
MX394296B (es) Producto en desarrollo de análisis de secuenciación de alineación y variante.
EA201890012A1 (ru) Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич
EP4406585A3 (en) Nucleic acid products and methods of administration thereof
WO2017070632A3 (en) Nucleobase editors and uses thereof
WO2016100955A3 (en) Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins
EP3843870C0 (en) MULTIPLE CHARGED IONIC COMPOUNDS DERIVED FROM POLYAMINES AND COMPOSITIONS BASED ON THESE COMPOUNDS AND ASSOCIATED PREPARATION METHODS
EP4303314A3 (en) Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection
MX2017004285A (es) Indicador biologico.
MX2020012350A (es) Anticuerpos anti-cd63, conjugados y usos de estos.
GB2564296A (en) Replicative transposon system
BR112013018744A2 (pt) método para produzir um polipetídeo ou uma proteína recombinante
WO2019055926A3 (en) Method for using aqueous two-phase system for the isolation, purification and/or concentration of short nucleic acid fragments
WO2017201102A8 (en) Method of improved sequencing by strand identification
MX2020012278A (es) Ensamblaje de polimero biologico habilitado para aprendizaje de maquina.
WO2018067582A3 (en) Hiv-1 env fusion peptide immunogens and their use
MX378585B (es) Sistema de expresion bacterial bicistronico
WO2019239218A3 (en) Determination of epigenetic modifications by nanopore sequencing

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLSC Publication of the preliminary search report

Effective date: 20181026

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20250705